WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Microbiome-Host Interactions: The Role of Gut Bacteria in Neurological Disorders

Omazia Nasir[1], Robina Bibi[2], Muhammad Usman Qamar[3], Arooj Fatima[4], Zarva Ahsan[5], Fawad Khan[6], Shahama Amjad[7]

[1]Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan (omazia106@gmail.com)
[2]Department of Psychology, National University of Modern Languages (NUML) Islamabad, Pakistan (robina2470@gmail.com)
[3]Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan (usmanvehari456@gmail.com)
[4]Department of Microbiology, Cholistan University of Veterinary and Animal Sciences Bahawalpur Pakistan (aroojfatima31202@gmail.com)
[5]Department of Livestock Management, Cholistan University of Veterinary and Animal Sciences Bahawalpur, Pakistan (dr.zarva.ahsan@gmail.com)
[6]Department of Microbiology, Hazara University Mansehra, Pakistan (khanfaawad@gmail.com)
[7]Faculty of Veterinary Sciences, Bahauddin Zakaria University Multan, Pakistan (shahamaamjad6@gmail.com)
DOI: https://doi.org/10.55248/gengpi.4.1023.102705

A B S T R A C T

Microbiome-host interactions have developed as an interesting field of study, illuminating the intricate the relations among the gut microbiota in addition to the central nervous system. The gut-brain axis, a bidirectional signaling pathway, plays an important function in influencing neurological function and the pathogenesis of various neurological sicknesses. Dysbiosis, An unbalance in the microbial ecology of the gut has been related to neurodevelopmental disorders, neurodegenerative diseases, mental health disorders, and neuroinflammatory conditions. This review article delves into the complex mechanisms underlying microbiome-host interactions in neurological disorders. It explores that gut microbiome's influence at inflammation plus immune responses, modulation of neurotransmitter systems, as well as the barrier between blood-brain integrity. The findings suggest that alterations may exist within the gut microbe community significantly influence neurological health, prompting the exploration of microbiome-based therapeutic strategies. Prebiotics, probiotics, fecal microbiota transplantation (FMT), diet, and lifestyle interventions have shown promise in modulating the gut microbiome and improving neurological outcomes in preclinical and clinical studies. However, challenges such as microbiome variability, standardization, safety considerations, and the need for mechanistic understanding require further investigation. The implications of this research for future studies are far-reaching. Personalized approaches to microbiome-based therapies, rigorous clinical trials, and identification of microbiome-brain biomarkers offer potential avenues to advance microbiome research into clinical practice. The promising role of microbiome modulation in neurological disorder management challenges conventional paradigms, paving the way for innovative and patient-centered treatments in precision medicine.

Keywords: Microbiome, Host interactions, Gut bacteria, Neurological disorders, Gut-brain axis.

1. Introduction

The human microbiome is complex and diverse a group of microbes, including bacteria, viruses, fungi, in addition to archaea, residing in and on the body of human(Hoffmann, Dollive et al. 2013). It is essential for preserving human health and has been implicated across a variety of physiological systems. Among the numerous microbiomes in the body of human, the gut microbiome stands out as one of the most influential, significantly affecting overall well-being and even having implications for neurological function(Peng, Tabashsum et al. 2020).

1.1 Overview of the Human Microbiome:

The microbiome of a person is a dynamic plus intricately balanced ecosystem that coexists with the host (Man, de Steenhuijsen Piters et al. 2017). It was estimated that there are trillions of microbial cells residing in a body of human, outnumbering human cells by a factor of ten (Zhu, Wang et al. 2010). This diverse collection of microorganisms primarily resides in a tract of gastrointestine, skin, oral cavity, respiratory tract, also urogenital system (Requena and Velasco 2021). Among these, the microbiome of gut, located in the intestinal tract, is the furthermost extensively studied and understood. A gut microbiome is made up of hundreds to thousands of dissimilar microbial species, with each individual harboring a unique and specific microbial profile. This diversity is influenced by many factors, including genetics, diet, environment, age, and lifestyle(Rinninella, Raoul et al. 2019). The gut microbiome is not merely a passive bystander; rather, it actively interacts with the host, playing vital roles in digestion, metabolism, immune system regulation, and even neural signaling(Zhang, Chen et al. 2023).

1.2 Gut-Brain Axis: The Link among the Microbiome plus Neurological Function:

This gut-brain axis serves as a system of mutual communication that links the gut with its microbiome to the central nervous system (CNS), together with a brain plus spinal cord(Baj, Moro et al. 2019). This intricate and multifaceted communication occurs through neural, endocrine, also immune pathways. The gut in addition to the brain communicate through the vagus nerve, the enteric nervous system (ENS), plus the release of various signalling substances such as neurotransmitters, cytokines, and hormones(Sun, Li et al. 2020). The gut-brain axis shows a major function in modulating several neurological functions, counting mood regulation, cognition, behavior, plus even pain perception. Gut microbes produce and secrete neurotransmitters in addition to neuromodulators, for example serotonin, dopamine, GABA (Gamma-Aminobutyric Acid), as well as short-chain fatty acid (SCFAs), that have an impact on behaviour and brain health(Wall, Cryan et al. 2014). Additionally, a gut microbiome's role in immune system regulation and inflammation can have profound effects on brain health and neurological disorders.

1.3 Importance of Studying Microbiome-Host Interactions in Neurological Disorders:

The increasing form of research on the gut-brain axis plus an impact of the gut microbiome on the neurological function has generated an expanding interest in studying microbiome-host interactions in neurological disorders(Kaur, Singh et al. 2021). Neurological disorders, such as neurodevelopmental disorders (e.g., autism, ADHD), neurodegenerative diseases (e.g., Alzheimer's, Parkinson's), mental health disorders (e.g., depression, anxiety), plus neuroinflammatory conditions (e.g., multiple sclerosis, stroke), have complex etiologies involving genetic, environmental, and lifestyle factors(Marć, Jastrząb et al. 2022). New research reveals that changes within content in addition to function of the gut microbiome might have a part in the aetiology of some diseases besides progression of various neurological disorders(Tilg, Cani et al. 2016). Dysbiosis, a microbial population imbalance within the gut had been associated to changes in the gut-brain axis communication and has been linked to neurological dysfunction and behavioral changes in both animal models and humans(Benakis, Martin-Gallausiaux et al. 2020). Studying microbiome-host interactions in neurological disorders offers promising avenues for novel diagnostic approaches, therapeutic interventions, and potential preventive strategies. Understanding how gut bacteria influence neurological function and impact disease progression might result in the creation of microbiome-based interventions to complement or enhance current treatments for neurological disorders(Zheng, Liwinski et al. 2020). The human microbiome, particularly the gut microbiota is vital for significant part in regulatory neurological function through the gut-brain axis. The study of microbiome-host interactions in neurological disorders is an exciting and rapidly evolving field that offers potential breakthroughs in understanding disease pathogenesis and developing novel therapeutic approaches for neurological disorders(Gebrayel, Nicco et al. 2022). As research continues to uncover the complicated connections among the brain plus the gut microbiota, it is becoming increasingly evident that this area of study holds considerable promise for improving neurological health and well-being(Hooks, Konsman et al. 2019).

2. The Gut Microbiome: Composition and Function

The microbiome of the gut is a sophisticated ecology made up of a diverse array of microorganisms that live in the digestive system, such as bacteria, viruses, fungus, and archaea(Hillman, Lu et al. 2017). Individual differences in the gut microbiome's make it very variable, and a number of variables, including nutrition, genetics, age, geography, along with lifestyle, can all have an impact(Bai, Sun et al. 2022).

2.1 Diversity and Dynamics of Gut Microbial Communities

Diversity of Gut Microbial Communities:

The gut microbiome is one of the greatest diverse microbial ecosystems in body of the human. It is estimated that there are approximately 500 to 1,000 different bacterial species residing in the human gut(Gilbert, Blaser et al. 2018). However, while there is a core set of bacteria shared among most individuals, there is also a substantial amount of inter-individual variation in gut microbial composition. This individual-specific microbial profile is shaped via a grouping of host genetics plus environmental aspects(Datta, Almada et al. 2018).

Dynamics of Gut Microbial Communities:

A gut microbial community is dynamic and can undergo rapid changes in response to various stimuli. Factors such as diet, medications (e.g., antibiotics), infections, and lifestyle changes can influence the abundance and diversity of gut microbes(Mirzaei and Maurice 2017). Additionally, the gut microbiome undergoes significant changes during critical developmental stages, such as early infancy and adolescence. These fluctuations in microbial composition can have implications for both gastrointestinal and neurological health(Rinninella, Raoul et al. 2019).

2.2 Factors Influencing Gut Microbiome Composition:

Several factors impact the gut microbiome's makeup, and understanding these influences is essential for unraveling the function of bacteria in gut in neurological disorders. Some of the key factors include:



Diet: One of the greatest important variables is diet in shaping the gut microbiome. Different types of diets, such as high-fiber, low-fat, or high-sugar diets, can lead to distinct microbial communities in the gut(Senghor, Sokhna et al. 2018). Fiber-rich diets, for example, encourage the development of good bacteria that make short-chain fatty acids (SCFAs), that has neuroprotective properties.

Antibiotics and Medications: The use of antibiotics and other medications can disturb the gut microbiome via changing balance of bacterial species. While antibiotics are essential for treating infections there over use or misuse can lead to dysbiosis, potentially impacting neurological health through the gut-brain axis (Patangia, Anthony Ryan et al. 2022). Host genetics also play a role in shaping the gut microbiome. Certain genetic factors may predispose individuals to host-specific microbial communities, which can influence the risk of neurological disorders.

Age and Development: The gut microbiome undergoes significant changes during different stages of life. Early-life factors, such as the method of delivery (césarean section vs. vaginal birth) and breastfeeding, can influence the initial microbial colonization in infants. Additionally, the gut microbiome continues to evolve throughout life, with age-related changes potentially affecting neurological function(Barone, D'Amico et al. 2022).

Environmental Factors: Geography, climate, and exposure to various environmental factors could effect the types of microbes that colonizing in the gut.

2.3 Gut Microbial Metabolites and their Impact on Neurological Health:

The importance of the gut microbiota in metabolizing dietary components plus producing numerous bioactive molecules that can influence neurological health Some key microbial metabolites include:

Short-Chain Fatty Acids (SCFAs): Acetate, propionate, as well as butyrate, among other SCFAs, are made by gut bacteria during the fermentation of dietary fiber. These SCFAs has shown to ensure anti-inflammatory and neuroprotective special effects, supporting brain health and potentially reducing the risk of neuroinflammatory disorders(Xiong, Zhou et al. 2022).

Neurotransmitters and Neuromodulators: Certain gut microbes have the ability to produce neurotransmitters and neuromodulators, including serotonin, dopamine, and GABA. These molecules can directly impact the gut-brain axis and influence mood, cognition, and behavior(Agirman and Hsiao 2021).

Bile Acid Metabolism: Gut bacteria can metabolize bile acids, That show a role in digestion of lipids. Some bile acid metabolites have connections to neurological conditions like Alzheimer's disease, suggesting a potential function for gut microbiome within neurodegeneration(Needham, Kaddurah-Daouk et al. 2020).

Trimethylamine N-Oxide (TMAO): Certain gut bacteria could metabolize dietary choline and L-carnitine to produce trimethylamine (TMA), which is further converted into TMAO in the liver. Raised TMAO levels had linked by an increased risk of cardiovascular disease, and recent research suggests a potential link between TMAO and neurological disorders as well(Janeiro, Ramírez et al. 2018).

Indole and Derivatives: Indole and its derivatives during digestion, gut bacteria create the breakdown of tryptophan, an essential amino acid. These compounds can modulate immune responses and may have implications for neurological disorders involving inflammation.(Ye, Li et al. 2022). Knowing the function of the gut microbial metabolites in neurological healthiness is a rapidly evolving area of research. These microbial products can have wide-

ranging effects on the gut-brain axis and might make available new objectives for therapeutic interventions in neurological disorders. However, further study is required to fully elucidate the mechanisms and prospective clinical applications of gut microbial metabolites in neurological health and disease(Marwede, Yassa et al. 2022).

3. Gut-Brain Axis: Communication Pathways

The gut-brain axis is a complex bidirectional announcement system that connects the gut and its microbiome to the spinal cord and brain make up the structure known as the central nervous system (CNS).This intricate network of communication pathways provides for communication between the stomach and the brain and is essential for controlling a number of physiological functions, including digestion, metabolism, immune response, and even behavior and mood(Kuwahara, Matsuda et al. 2020).

3.1 Neural Pathways:

One of the major communication pathways in the gut-brain axis involves neural connections among the gut in addition the brain. The enteric nervous system (ENS), often referred to as the "second brain," is a complex network of neurons which spans the entire gastrointestinal tract. The ENS has a large number of neuronal connections with the brain and can function apart from the CNS(Schneider, Wright et al. 2019). The ENS can sense and respond for the changes in environment of the gut, for example the availability of nutrients or injurious substances. It can then send signals to the brain via the vagus nerve, which is the longest cranial nerve in the body. The vagus nerve serves as a major conduit for bidirectional communication between the gut and the brain. It carries sensory information from the gut to the brain, providing feedback on gut conditions and microbial activity(Forsythe, Bienenstock et al. 2014). Conversely, the brain can send signals back to the gut via the vagus nerve, influencing gut motility, secretion of digestive enzymes, and gut permeability. This gut-brain neural communication is essential for coordinating gastrointestinal functions and maintaining gut homeostasis(Carabotti, Scirocco et al. 2015).

3.2 Immune System and Neurotransmitter Communication:

Another critical pathway in the gut-brain axis involves immune system and neurotransmitter communication. The gut houses a significant portion of the body's immune cells, and the gut microbiome plays a key role in regulating immune function. Gut microbes can interact with immune cells in the gut-associated lymphoid tissue (GALT) and the mucosal immune system, influencing immune responses and inflammation. Cytokines and other immune signaling molecules produced in response to gut microbial activity can enter the bloodstream and pass the barrier between blood and brain, Allowing them to communicate with a brain also affect neurological function.(Sanz and De Palma 2009) Inflammation in the gut, driven by dysbiosis or immune responses to pathogens, can trigger neuroinflammation and take part in the growth or exacerbation of neurological disorders. Moreover, certain gut microbes are capable of producing neurotransmitters and neuromodulators, such as serotonin, dopamine, and GABA. These microbial-produced molecules can directly interact with nerve endings in the gut lining, triggering neural signals that are transmitted to the brain. Additionally, some of these neurotransmitters can enter the bloodstream and reach the brain, impacting mood and behavior(Burokas, Moloney et al. 2015).

3.3 Vagal Nerve Signaling:

The vagus nerve, in addition to its role in neural pathways, is a primary route for transmitting chemical signals between the gut and the brain. It is a crucial part of the parasympathetic nervous system, often referred as the "rest and digest" system, which counterbalances the "fight or flight" response of the sympathetic nervous system(VanPatten and Al-Abed 2017). Vagal nerve signaling between the gut and the brain can influence brain function, emotional regulation, and stress responses. Activation of the vagus nerve can trigger the release of acetylcholine, a neurotransmitter that has calming and anti-inflammatory effects in the brain. Vagal nerve stimulation has been studied as a potential therapeutic approach for various neurological disorders, including epilepsy and depression(Bonaz, Sinniger et al. 2021).

3.4 Microbial Molecules and Signaling:

The gut microbiome itself yields a wide variety of bioactive molecules which could impact both the gut as well as the brain. Microbial metabolites, including indole compounds and short-chain fatty acids (SCFAs),might had straight special effects on gut cells, immune cells, plus neurons in the ENS. These metabolites can also enter the bloodstream and reach the brain, where they can influence neural function and behavior(Ansari, Neshat et al. 2023). Additionally, gut microbes can produce neuroactive compounds, such as serotonin and GABA, which can directly interact with the gut lining or be released into circulation to affect the brain. Some gut bacteria also produce molecules that mimic or interfere with human neurotransmitters, further influencing neural signaling.

Microbial molecules can act as signaling molecules that regulate gene expression in gut epithelial cells and immune cells, affecting gut barrier function and immune responses. Dysregulation of these microbial signaling pathways had been associated within several gut and neurological disorders(Yoo, Groer et al. 2020). The gut-brain axis involves intricate communication pathways that allow bidirectional signaling in-between a gut, its microbiome, plus the brain. This communication pathway involve neural connections, immune signaling, vagal nerve transmission, and the production of microbial molecules that influence gut and neurological health(Patrono, Svoboda et al. 2021). Understanding the gut-brain axis is essential for unraveling the role

of gut bacteria in neurological disorders and holds potential for developing to support brain health and cure neurological diseases, various therapeutic approaches that target the gut microbiota have been developed(Suganya and Koo 2020).

4. Microbiome and Neurodevelopmental Disorders

Neurodevelopmental disorders a collection of illnesses known as disorders are characterised by impairments in brain function that affect an individual's cognitive, emotional, social, and behavioral development. Recent research has implicated the gut microbiome as a potential contributing feature in the growth and development of various neurodevelopmental disorders(Sivamaruthi, Suganthy et al. 2020). Here's a detailed look at the association among the gut microbiome plus some neurodevelopmental disorders:

4.1 Autism Spectrum Disorders (ASD):

A range of complicated neurodevelopmental disorders known as autism spectrum disorders (ASD) generally defined by difficulties in social interaction and communication as well as by constrained, repetitive patterns of behaviour and interests. Although the precise origin of ASD is still unknown, it is thought that both genetic and environmental factors are involved. ASD pathophysiology may be influenced by the gut microbiota, according to emerging research(Pelphrey, Shultz et al. 2011). Numerous investigations have discovered variations in the gut microbial makeup of people with ASD in comparison to people who are usually developing. Dysbiosis, characterized by alterations in specific bacterial taxa, reduced microbial diversity, and imbalanced microbial metabolites, has been observed in some individuals with ASD. The gut microbiome can influence brain development and function through the gut-brain axis. Microbial metabolites, such as SCFAs, can modulate brain development and synaptic plasticity, potentially affecting cognitive and behavioral functions. Additionally, gut microbes can produce neuroactive compounds, such as serotonin and GABA, which may influence neural signaling relevant to ASD symptoms(Silva, Bernardi et al. 2020). Furthermorethe gut microbiota influences the immune system regulation, and alterations in the gut microbial community can lead to increased inflammation, which has been linked to ASD. Immune dysregulation in the gut and systemic inflammation may impact neurodevelopment during critical periods of brain growth and maturation.

4.2 Attention Deficit Hyperactivity Disorder (ADHD):

A neurodevelopmental illness called Attention Deficit Hyperactivity illness (ADHD) is characterised by signs of impulsivity, hyperactivity, and inattention. The etiology of ADHD is complex and involves a combination of genetic, environmental, and neurobiological factors. Although research on the gut microbiome's role in ADHD is still in its early stages, according to several research, people via ADHD and neurotypical controls have different gut microbial compositions(Kieling, Goncalves et al. 2008). Dysbiosis and alterations in specific bacterial taxa have been associated with ADHD symptoms. The gut-brain axis might also perform a r in ADHD, as gut microbes can produce neurotransmitters and neuromodulators that influence neural signaling relevant to ADHD symptoms. Additionally, the gut microbiome's influence on immune function and inflammation may be relevant, as immune dysregulation has been implicated in the pathophysiology of ADHD(Bull-Larsen and Mohajeri 2019).

It is significant to check that the association among the gut microbiome plus ADHD is complex and multifactorial. More study is required to completely comprehend the processes through that gut microbes may contribute to ADHD and how interventions targeting the gut microbiome might impact symptomatology(Mathee, Cickovski et al. 2020).



4.3 Intellectual Disabilities and Learning Disorders:

Intellectual disabilities and learning disorders encompass a range of circumstances characterised by impairments in intellectual functioning as well as adaptive behaviour. These disorders often manifest during childhood and can have diverse causes, including genetic, environmental, and prenatal factors(Van Karnebeek, Shevell et al. 2014). While research on the gut microbiome's role in intellectual disabilities and learning disorders is limited, some research had suggested relations among gut microbial dysbiosis and cognitive impairments. For example, imbalances within the gut microbiome had been stated within individual with Down syndrome, a genetic condition associated with intellectual disabilities. The effect of gut microbiome's on immune function and inflammation may also be relevant to intellectual disabilities and learning disorders, as chronic inflammation could impact brain development and function during critical periods of growth(Iliodromiti, Triantafyllou et al. 2023). However, more research is required to develop a clear link between the gut microbiome and specific intellectual disabilities or learning disorders. Understanding the gut-brain axis's part in these conditions may offer new avenues for potential interventions and therapies to support cognitive development and learning in individuals that are effected(Faraj, Takanti et al. 2021).

The function of the gut microbiome in neurodevelopmental diseases such autism spectrum disorders and attention deficit hyperactivity disorder, and intellectual disabilities, is an area of growing interest and active research(Martins, Bandarra et al. 2020). While there is evidence to support alterations within the gut microbial community may be associated with these conditions, the underlying mechanisms and causality remain complex and not completely understood. More study is required to determine the specific relationships among the gut microbiome, the gut-brain axis, as well as neurodevelopmental disorders, along with an ultimate goal to developing targeted interventions to improve outcomes for affected individuals(Liu, Li et al. 2019).

5. Gut Microbiome and Neurodegenerative Diseases

Neurodegenerative diseases were a class of chronic, progressive conditions marked by the slow degeneration along with loss of neurons within the central nervous system. While the exact causes of most neurodegenerative diseases remain elusive, emergent indication recommends that the gut microbiome might perform a significant part in their pathogenesis plus progression(Deeb and Nabulsi 2020).

5.1 Alzheimer's Disease:

Alzheimer's disease (AD) is a particularly prevalent kind of dementia, and is distinguished through a gradual deterioration in memory loss, cognitive function, also changes in behavior and personality. The pathology of a formation of amyloid-beta plaques along with tau protein tangles within the brain characterises Alzheimer's disease(Zis and Strydom 2018). Recent research had presented that variations within the gut microbiome composition in addition to function can influence AD pathogenesis. Studies in both animal models and humans have demonstrated variances within the gut microbial community among individual heaving AD plus healthy control. Dysbiosis, reduced microbial diversity, and changes in specific bacterial taxa have been observed in AD patients(Johnson 2020). The gut microbiome can influence AD through several mechanisms, including the gut-brain axis, immune system modulation, also microbial metabolite production. Short-chain fatty acids (SCFAs), for example, were metabolites formed via microorganisms can have neuroprotective effects and may help reduce neuroinflammation and amyloid-beta accumulation(Silva, Bernardi et al. 2020). Dysbiosis and gut permeability may also contribute to systemic inflammation, which can exacerbate neuroinflammation and neurodegeneration. Moreover, the gut microbiome plays a part for the metabolism of bile acids, that is involved in lipid transport plus metabolism. Altered bile acid metabolism in the gut may impact the enterohepatic circulation of bile acids, affecting the clearance of amyloid-beta from the brain(Connell, Le Gall et al. 2022).

5.2 Parkinson's Disease:

Parkinson's disease (PD) is a progressive neurodegenerative disorder categorized with motor symptoms, including tremors, rigidity, in addition to bradykinesia. The reduction of dopaminergic neurons within the substantia nigra area of the brain is connected with Parkinson's disease(Capriotti and Terzakis 2016). Emerging evidence suggests a connection between the gut microbiome in addition to PD. Search had revealed variations within the gut microbial community in individuals heaving PD compared to healthy controls. Dysbiosis, reduced microbial diversity, and changes in specific bacterial taxa have been reported in patients heaving PD(Fan, Sheng et al. 2022). The gut-brain axis is thought for playing a critical function in PD pathogenesis. Alpha-synuclein, a protein associated with PD pathology, can propagate from the gut to the brain, potentially triggering the misfolding and aggregation of alpha-synuclein within a brain. Alpha-synuclein aggregates can then spread throughout the CNS, contributing to the progressive neurodegeneration observed in PD. Furthermore, gut microbes can produce neuroactive compounds, such as neurotransmitters and SCFAs, which can influence neuronal function and neurotransmission relevant to PD symptoms. Microbial metabolites may also impact the immune system, inflammation, as well as the integrity of the barrier between blood and brain, all of that had implications for PD pathophysiology.

5.3 Amyotrophic Lateral Sclerosis (ALS):

Amyotrophic Lateral Sclerosis (ALS) is a type of neurodegenerative illness that affects motor neurons within the brain and spinal cord. The particular reason of ALS although it is not completely understood, either genetic plus environmental variables are considered to have a part in its development. Research on the gut microbiome and ALS is still relatively limited, but some studies have reported alterations within a gut microbial community among

individuals with ALS as comparison to healthy controls(Naganska and Matyja 2011). Dysbiosis, reduced microbial diversity, and changes in specific bacterial taxa had been associated with ALS. The gut-brain axis might also take a part in ALS. In some cases, neuroinflammation and immune system dysregulation in the gut could contribute to systemic inflammation, potentially exacerbating neuroinflammation in the CNS and contributing to motor neuron degeneration(Zhu, Li et al. 2020). Moreover, gut microbes can produce neuroactive compounds and metabolites that can influence neuronal function and immune responses. These microbial-produced molecules might effect ALS development over their effects proceeding neural signaling, inflammation, and oxidative stress(Ullah, Arbab et al. 2023). The gut microbiome's role Alzheimer's disease, Parkinson's disease, along with amyotrophic lateral sclerosis are examples of neurodegenerative disorders is a rapidly evolving area of research. While there is accumulating evidence supporting the association among the gut microbiome and neurodegeneration, the underlying mechanisms and causality are still being investigated. Understanding the intricate interactions among the gut microbiome, as well as the gut-brain axis, plus the pathogenesis of neurodegenerative diseases holds potential for the advancement of novel therapeutic approaches for modify disease progression to improve the quality of life for affected individuals(Gubert, Kong et al. 2020).

7. Gut Microbiome and Neuroinflammatory Disorders

Neuroinflammatory disorders are characterized by inflammation in the central nervous system (CNS), which can lead to damage and dysfunction of nerve cells and tissues. Emerging research indicates that the gut microbiome may play a role in the pathogenesis and progression of neuroinflammatory disorders(Bairamian, Sha et al. 2022). Here's a detailed look at the relationship between the gut microbiome and some neuroinflammatory disorders:

7.1 Multiple Sclerosis (MS):

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the myelin sheath surrounding nerve fibers in the CNS. This demyelination leads to disrupted nerve signaling and various neurological symptoms, such as weakness, numbness, visual disturbances, and difficulties with coordination and balance. The gut microbiome has been implicated in the development and modulation of MS.Studies have shown that individuals with MS have alterations in their gut microbial composition compared to healthy controls(Pithadia, Jain et al. 2009). Dysbiosis, characterized by changes in specific bacterial taxa and reduced microbial diversity, has been observed in MS patients. The gut microbiome can influence MS through the gut-brain axis and its impact on immune system regulation and inflammation. Dysbiosis may lead to increased gut permeability, allowing harmful microbial products and metabolites to enter the bloodstream and trigger systemic inflammation(Schepici, Silvestro et al. 2019). This systemic inflammation can promote neuroinflammation in the CNS, contributing to demyelination and MS progression. Additionally, the gut microbiome can influence the balance of pro-inflammatory and anti-inflammatory immune responses. Certain gut microbes can induce the production of regulatory T-cells and anti-inflammatory cytokines, which may help suppress autoimmunity and inflammation associated with MS(Haase, Haghikia et al. 2018). Furthermore, microbial metabolites, such as short-chain fatty acids (SCFAs), produced during the fermentation of dietary fiber by gut microbes, have been shown to have anti-inflammatory effects. SCFAs may help modulate the immune response in MS and contribute to neuroprotection.

7.2 Stroke:

Stroke is a medical emergency that occurs when blood flow to the brain is disrupted, leading to brain cell damage and potentially permanent neurological deficits. Stroke can be caused by either a blocked artery (ischemic stroke) or bleeding in the brain (hemorrhagic stroke). The gut microbiome's role in stroke is an emerging area of research. Studies have suggested that gut microbial dysbiosis may be associated with stroke risk factors, such as hypertension, diabetes, and obesity(Nagel, Mahalingam et al. 2010). Dysbiosis may contribute to systemic inflammation and metabolic disturbances, which are known risk factors for stroke. In animal models, alterations in the gut microbiome have been shown to influence stroke outcomes. Transplanting the gut microbiome from healthy animals to stroke-prone animals resulted in reduced stroke severity and improved neurological outcomes, suggesting a potential protective role of a healthy gut microbial community in stroke. The gut microbiome may also play a role in stroke recovery. Animal studies have shown that gut microbial composition can influence post-stroke neuroplasticity and functional recovery(Zhao, Liu et al. 2021). However, more research is needed to fully understand the specific mechanisms through which the gut microbiome may impact stroke risk, severity, and recovery in humans. The gut-brain axis's role in stroke pathophysiology and recovery remains an active area of investigation.

7.3 Epilepsy:

Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. The exact causes of epilepsy are varied and can involve genetic, structural, and acquired factors. Research on the gut microbiome and epilepsy is still in its early stages, but some studies have reported differences in gut microbial composition between individuals with epilepsy and healthy controls(Brodie, Zuberi et al. 2018). Dysbiosis and changes in specific bacterial taxa have been associated with epilepsy. The gut microbiome can influence epilepsy through the gut-brain axis and its impact on inflammation and neurotransmitter systems. Dysbiosis may lead to increased gut permeability and inflammation, potentially affecting the brain's electrical activity and seizure thresholds. Moreover, gut microbes can produce neurotransmitters and neuromodulators, such as gamma-aminobutyric acid (GABA), which play a critical role in inhibiting excessive neuronal excitability(Leclercq, Le Roy et al. 2020). Alterations in GABA-producing gut microbes may impact GABA levels in the brain and contribute to seizure activity. Some research suggests that the ketogenic diet, a high-fat, low-carbohydrate diet used to treat certain types of epilepsy, may also impact the gut microbiome. The diet alters gut microbial composition, and some studies suggest that the gut microbiome may play a role in the diet's anti-seizure effects(Ding, Lang et al. 2021). The gut microbiome's role in

neuroinflammatory disorders, such as multiple sclerosis, stroke, and epilepsy, is a rapidly evolving area of research. While there is evidence to suggest a link between gut microbial dysbiosis and these neuroinflammatory conditions, the underlying mechanisms and causality are still being investigated(Rutsch, Kantsjö et al. 2020). Understanding the interactions between the gut microbiome, the gut-brain axis, and neuroinflammatory disorders may open new avenues for targeted interventions and potential therapeutic strategies to modulate inflammation and improve neurological outcomes.

8. Mechanisms Underlying Microbiome-Host Interactions in Neurological Disorders

The gut microbiome plays a crucial role in influencing the development and function of the central nervous system (CNS) through a complex network of interactions with the host. These interactions involve multiple mechanisms that can have significant implications for neurological health and disease(Fung, Olson et al. 2017). Here's a detailed look at some of the key mechanisms underlying microbiome-host interactions in neurological disorders:

8.1 Inflammation and Immune Response:

The gut microbiome has a profound impact on the host's immune system, and dysregulation of immune responses is often implicated in neurological disorders. Microbial products, such as lipopolysaccharides (LPS), peptidoglycans, and other bacterial metabolites, can trigger immune responses when they enter the bloodstream via a leaky gut or interact with immune cells in the gut-associated lymphoid tissue (GALT)(Fung, Olson et al. 2017).

In some cases, an imbalanced gut microbial community, known as dysbiosis, can lead to increased gut permeability (leaky gut), allowing harmful microbial products and metabolites to enter the bloodstream and trigger systemic inflammation. This systemic inflammation can have far-reaching effects on the CNS, contributing to neuroinflammation and neuronal damage, which is observed in various neurological disorders. Chronic inflammation is associated with many neurological conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy(Simon, McGeachy et al. 2017). Inflammatory cytokines and immune cells can cross the blood-brain barrier and exert harmful effects on brain tissue, exacerbating neurodegeneration and contributing to disease progression. On the other hand, some beneficial gut microbes and microbial metabolites can promote anti-inflammatory responses and immune tolerance, protecting the host from excessive inflammation and its potential impact on neurological health(Parker, Fonseca et al. 2020).

8.2 Modulation of Neurotransmitter Systems:

Gut microbes can produce and modulate various neuroactive compounds, including neurotransmitters and neuromodulators, which can influence neural signaling and brain function. The gut-brain axis allows these neuroactive compounds to directly impact the CNS and influence neurological disorders(Strandwitz 2018). For instance, some gut microbes are capable of producing neurotransmitters like serotonin, dopamine, and gamma-aminobutyric acid (GABA). These neurotransmitters play critical roles in mood regulation, cognitive function, and emotional responses. Dysbiosis may alter the production and availability of these neurotransmitters, potentially contributing to the development of mood disorders, anxiety disorders, and other neuropsychiatric conditions(Socała, Doboszewska et al. 2021). Moreover, the gut microbiome can influence the expression and function of receptors for various neurotransmitters in the brain. Alterations in receptor expression can affect the sensitivity and responsiveness of neural circuits, further contributing to neurological disorders. Notably, the microbiome-gut-brain axis can also influence the hypothalamic-pituitary-adrenal (HPA) axis, a key component of the body's stress response system. Gut microbes can impact stress hormone levels and influence the body's ability to cope with stress, which is relevant to many neurological and mental health disorders(Du, Gao et al. 2020).

8.3 Blood-Brain Barrier Integrity:

The blood-brain barrier (BBB) is a specialized barrier that separates the bloodstream from the brain tissue. It plays a crucial role in protecting the brain from harmful substances and maintaining a stable brain environment. Dysfunction of the BBB is associated with various neurological disorders, as it can allow immune cells, pathogens, and other harmful molecules to enter the brain(Kadry, Noorani et al. 2020).

Recent research suggests that the gut microbiome can influence BBB integrity through immune-mediated mechanisms. Dysbiosis and inflammation in the gut can lead to systemic inflammation, which may impact the BBB and compromise its integrity. Additionally, gut microbes can produce metabolites, such as trimethylamine-N-oxide (TMAO), that have been implicated in BBB dysfunction and neuroinflammation(Parker, Fonseca et al. 2020). Dysbiosis and the resulting increase in specific microbial metabolites may contribute to BBB disruption and contribute to the pathogenesis of neurological disorders. Furthermore, the gut microbiome can influence the expression of tight junction proteins in the gut lining, which play a crucial role in maintaining gut barrier function. Dysfunction of these tight junction proteins can lead to increased gut permeability, allowing harmful substances to cross the gut barrier and potentially impact BBB integrity(Genua, Raghunathan et al. 2021). Understanding the mechanisms underlying microbiome-host interactions in neurological disorders is crucial for developing targeted interventions and therapeutic strategies. Manipulating the gut microbiome through diet, prebiotics, probiotics, and fecal microbial transplantation holds promise as a potential approach to modulate these mechanisms and improve neurological health. However, further research is needed to fully elucidate the intricate and multifaceted interactions between the gut microbiome and the CNS in health and disease(Varesi, Campagnoli et al. 2023).

9. Therapeutic Strategies and Future Directions

The gut microbiome has emerged as a promising target for therapeutic interventions in various health conditions, including neurological disorders. Modulating the gut microbial community through different approaches offers potential opportunities to improve neurological health and manage neurological disorders(Berding and Cryan 2022). Here's a detailed note on some of the therapeutic strategies and future directions:

9.1 Probiotics and Prebiotics:

Probiotics are live microorganisms that, when administered in adequate amounts, can confer health benefits to the host. They are typically strains of beneficial bacteria that can help restore and maintain a healthy gut microbial balance. Probiotics have been investigated for their potential effects on neurological health through the gut-brain axis(Fijan 2014). Research on probiotics has shown promising results in improving symptoms of depression, anxiety, and cognitive function in some neurological disorders. Certain probiotic strains, such as Bifidobacterium and Lactobacillus species, have been studied for their effects on neurotransmitter production, inflammation reduction, and gut barrier integrity.

Prebiotics, on the other hand, are non-digestible food components that selectively promote the growth and activity of beneficial gut microbes. By providing a favorable environment for beneficial bacteria, prebiotics can support a healthy gut microbiome(Okolie, CK Rajendran et al. 2017). Future directions in this area involve identifying specific probiotic strains and prebiotic compounds that have the most significant impact on neurological health. Precision medicine approaches that consider an individual's unique gut microbial composition and health status may help optimize the effectiveness of probiotic and prebiotic interventions(Aziz, Doré et al. 2013).

9.2 Fecal Microbiota Transplantation (FMT):

Fecal microbiota transplantation (FMT) involves the transfer of fecal material from a healthy donor to a recipient with dysbiosis or a specific medical condition. FMT has been most widely used for the treatment of recurrent Clostridioides difficile infection, but its potential applications extend to neurological disorders as well. While research on FMT for neurological disorders is still in its early stages, studies have shown that changes in the gut microbiome can influence the gut-brain axis and neurological function(Gupta, Allen-Vercoe et al. 2016). FMT holds promise as a potential therapeutic approach for conditions like multiple sclerosis, Parkinson's disease, and autism spectrum disorders. Future directions in FMT research include identifying appropriate donor selection criteria, standardizing FMT protocols, and understanding the long-term safety and efficacy of the procedure. Advancements in microbial analysis techniques and precision medicine may lead to personalized FMT approaches tailored to individual patient needs(Tkach, Dorofeyev et al. 2023).

9.3 Diet and Lifestyle Interventions:

Diet and lifestyle play a significant role in shaping the gut microbial community and influencing neurological health. A healthy and balanced diet, rich in fruits, vegetables, whole grains, and lean proteins, can promote a diverse and beneficial gut microbiome. Certain dietary patterns, such as the Mediterranean diet, have been associated with a lower risk of cognitive decline and neurological disorders(Conlon and Bird 2014). This diet is high in fiber, antioxidants, and healthy fats, which can support gut microbial diversity and modulate the gut-brain axis. Regular physical activity, stress reduction techniques, and adequate sleep are essential lifestyle factors that can influence the gut microbiome and neurological health. Exercise has been shown to promote the growth of beneficial gut bacteria and reduce inflammation(Berding, Vlckova et al. 2021).

Future directions in diet and lifestyle interventions involve understanding the specific mechanisms through which these factors impact the gut-brain axis. Personalized nutrition and lifestyle recommendations based on an individual's gut microbial profile and health status may lead to more targeted and effective interventions(Tan, Lim et al. 2022).

9.4 Challenges and Opportunities in Microbiome-based Therapies:

While the potential of microbiome-based therapies is promising, there are several challenges and opportunities to consider:

1. Microbiome Variability: The gut microbiome is highly individualized and can vary significantly between individuals. Personalized approaches to microbiome-based therapies are crucial to ensure their efficacy(Cammarota, Ianiro et al. 2020).
2. Standardization and Regulation: Developing standardized protocols for probiotics, prebiotics, and FMT is essential to ensure consistent and reproducible results. Additionally, regulatory considerations and safety guidelines must be established for these therapies(Zubeldia-Varela, Barber et al. 2020).
3. Mechanistic Understanding: A deeper understanding of the mechanisms underlying the gut-brain axis and microbiome-host interactions is needed to develop targeted and effective interventions(Berding, Vlckova et al. 2021).
4. Long-term Safety and Efficacy: The long-term safety and efficacy of microbiome-based therapies need to be thoroughly evaluated in clinical trials(Paquet, Claus et al. 2021).

5. Combination Therapies: Combining different microbiome-based interventions, such as probiotics, prebiotics, and FMT, may offer synergistic effects and enhanced therapeutic benefits(Gulliver, Young et al. 2022).

Overall, the study of the gut microbiome and its impact on neurological health presents exciting opportunities for developing novel therapeutic strategies. Advances in microbiome research, precision medicine, and technology will likely lead to personalized and effective microbiome-based therapies for neurological disorders in the future. However, more research is needed to address challenges and fully harness the therapeutic potential of the gut-brain axis in improving neurological outcomes.

10. Conclusion

In conclusion, the emerging field of microbiome-host interactions has shed light on the crucial role of gut bacteria in influencing neurological health and the pathogenesis of various neurological disorders(Gebrayel, Nicco et al. 2022). Through the intricate gut-brain axis, the gut microbiome communicates with the central nervous system, impacting neurological function through a myriad of mechanisms. Dysbiosis, characterized by an imbalance in the gut microbial community, has been implicated in the development and progression of neurodevelopmental disorders, neurodegenerative diseases, mental health disorders, and neuroinflammatory conditions(Singh, Singh et al. 2022). Key findings have highlighted the involvement of inflammation and immune responses, modulation of neurotransmitter systems, and the integrity of the blood-brain barrier as critical factors in microbiome-host interactions in neurological disorders(Parker, Fonseca et al. 2020). These findings offer promising avenues for developing microbiome-based therapeutic strategies aimed at modulating the gut microbial community to improve neurological health and manage neurological disorders. Probiotics, prebiotics, fecal microbiota transplantation (FMT), diet, and lifestyle interventions represent potential therapeutic approaches that have shown encouraging results in preclinical and clinical studies. However, challenges such as microbiome variability, standardization, safety considerations, and the need for mechanistic understanding remain areas of active research(Baghai Arassi, Zeller et al. 2020).

The implications of these findings for future research are vast, emphasizing the importance of further exploring the intricate mechanisms underlying microbiome-host interactions. Understanding personalized approaches to microbiome-based therapies, conducting rigorous clinical trials, and identifying microbiome-brain biomarkers will play pivotal roles in translating microbiome research into clinical practice(Rahman, Islam et al. 2022). The promising role of microbiome modulation in neurological disorder management challenges the conventional understanding of neurological diseases and opens up new horizons in precision medicine. As we continue to deepen our knowledge of the gut-brain axis and microbiome-host interactions, innovative and patient-centered therapies hold the potential to revolutionize the treatment landscape for neurological disorders, improving patient outcomes and overall well-being(Chakrabarti, Geurts et al. 2022). Ultimately, this research has the potential to lead us towards more effective, targeted, and personalized interventions, offering hope for a better future for individuals affected by neurological disorders.

References

Agirman, G. and E. Y. Hsiao (2021). "SnapShot: The microbiota-gut-brain axis." Cell **184**(9): 2524-2524. e2521.

Ansari, F., et al. (2023). "The role of probiotics and prebiotics in modulating of the gut-brain axis." Frontiers in Nutrition **10**: 1173660.

Aziz, Q., et al. (2013). "Gut microbiota and gastrointestinal health: current concepts and future directions." Neurogastroenterology & Motility **25**(1): 4-15.

Baghai Arassi, M., et al. (2020). "The gut microbiome in solid organ transplantation." Pediatric Transplantation **24**(7): e13866.

Bai, X., et al. (2022). "Landscape of the gut archaeome in association with geography, ethnicity, urbanization, and diet in the Chinese population." Microbiome **10**(1): 147.

Bairamian, D., et al. (2022). "Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer's disease." Molecular neurodegeneration **17**(1): 1-23.

Baj, A., et al. (2019). "Glutamatergic signaling along the microbiota-gut-brain axis." International Journal of Molecular Sciences **20**(6): 1482.

Barone, M., et al. (2022). "Age-related diseases, therapies and gut microbiome: A new frontier for healthy aging." Mechanisms of Ageing and Development **206**: 111711.

Benakis, C., et al. (2020). "The microbiome-gut-brain axis in acute and chronic brain diseases." Current opinion in neurobiology **61**: 1-9.

Berding, K. and J. F. Cryan (2022). "Microbiota-targeted interventions for mental health." Current opinion in psychiatry **35**(1): 3.

Berding, K., et al. (2021). "Diet and the microbiota–gut–brain axis: sowing the seeds of good mental health." Advances in Nutrition **12**(4): 1239-1285.

Bonaz, B., et al. (2021). "Therapeutic potential of vagus nerve stimulation for inflammatory bowel diseases." Frontiers in neuroscience **15**: 650971.

Brodie, M. J., et al. (2018). "The 2017 ILAE classification of seizure types and the epilepsies: what do people with epilepsy and their caregivers need to know?" Epileptic Disorders **20**(2): 77-87.

Bull-Larsen, S. and M. H. Mohajeri (2019). "The potential influence of the bacterial microbiome on the development and progression of ADHD." Nutrients **11**(11): 2805.

Burokas, A., et al. (2015). "Microbiota regulation of the mammalian gut–brain axis." Advances in applied microbiology **91**: 1-62.

Cammarota, G., et al. (2020). "Gut microbiome, big data and machine learning to promote precision medicine for cancer." Nature reviews Gastroenterology & hepatology **17**(10): 635-648.

Capriotti, T. and K. Terzakis (2016). "Parkinson disease (PD) is a progressive neurodegenerative disease that affects one million people in the United States." This article reviews the etiology and pathophysiology of PD, risk factors, clinical manifestations, diagnostic criteria, and treatment of this common disease. Implications for home care clinicians are included **8**.

Carabotti, M., et al. (2015). "The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems." Annals of gastroenterology: quarterly publication of the Hellenic Society of Gastroenterology **28**(2): 203.

Carlessi, A. S., et al. (2021). "Gut microbiota–brain axis in depression: The role of neuroinflammation." European Journal of Neuroscience **53**(1): 222-235.

Cenit, M. C., et al. (2017). "Influence of gut microbiota on neuropsychiatric disorders." World journal of gastroenterology **23**(30): 5486.

Chakrabarti, A., et al. (2022). "The microbiota–gut–brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice." Cellular and Molecular Life Sciences **79**(2): 80.

Chen, Y., et al. (2021). "Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders." Nutrients **13**(6): 2099.

Conlon, M. A. and A. R. Bird (2014). "The impact of diet and lifestyle on gut microbiota and human health." Nutrients **7**(1): 17-44.

Connell, E., et al. (2022). "Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia." Molecular neurodegeneration **17**(1): 43.

Craske, M. G., et al. (2011). "What is an anxiety disorder?" Focus **9**(3): 369-388.

Datta, M. S., et al. (2018). "Inter-individual variability in copepod microbiomes reveals bacterial networks linked to host physiology." The ISME Journal **12**(9): 2103-2113.

Deeb, O. and M. Nabulsi (2020). "Exploring multiple sclerosis (MS) and amyotrophic lateral scler osis (ALS) as neurodegenerative diseases and their treatments: a review study." Current Topics in Medicinal Chemistry **20**(26): 2391-2403.

Di Marzo, V. (2022). "The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders." Dialogues in clinical neuroscience.

Ding, M., et al. (2021). "Microbiota–gut–brain axis and epilepsy: a review on mechanisms and potential therapeutics." Frontiers in Immunology **12**: 742449.

Du, Y., et al. (2020). "Crosstalk between the microbiota-gut-brain axis and depression." Heliyon **6**(6).

Fan, H. X., et al. (2022). "New hope for Parkinson's disease treatment: Targeting gut microbiota." CNS Neuroscience & Therapeutics **28**(11): 1675-1688.

Faraj, L. J., et al. (2021). "The gut-brain axis: Literature overview and psychiatric applications." Federal Practitioner **38**(8): 356.

Farzi, A., et al. (2018). "Gut microbiota and the neuroendocrine system." Neurotherapeutics **15**: 5-22.

Fijan, S. (2014). "Microorganisms with claimed probiotic properties: an overview of recent literature." International journal of environmental research and public health **11**(5): 4745-4767.

Forsythe, P., et al. (2014). "Vagal pathways for microbiome-brain-gut axis communication." Microbial endocrinology: The microbiota-gut-brain axis in health and disease: 115-133.

Fung, T. C., et al. (2017). "Interactions between the microbiota, immune and nervous systems in health and disease." Nature neuroscience **20**(2): 145-155.

Gebrayel, P., et al. (2022). "Microbiota medicine: Towards clinical revolution." Journal of Translational Medicine **20**(1): 1-20.

Genua, F., et al. (2021). "The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development." Frontiers in Oncology **11**: 626349.

Gilbert, J. A., et al. (2018). "Current understanding of the human microbiome." Nature medicine **24**(4): 392-400.

Gubert, C., et al. (2020). "Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases." Neurobiology of disease **134**: 104621.

Gulliver, E. L., et al. (2022). "the future of microbiome-based therapeutics." Alimentary Pharmacology & Therapeutics **56**(2): 192-208.

Gupta, S., et al. (2016). "Fecal microbiota transplantation: in perspective." Therapeutic advances in gastroenterology **9**(2): 229-239.

Haase, S., et al. (2018). "Impacts of microbiome metabolites on immune regulation and autoimmunity." Immunology **154**(2): 230-238.

Hillman, E. T., et al. (2017). "Microbial ecology along the gastrointestinal tract." Microbes and environments **32**(4): 300-313.

Hoffmann, C., et al. (2013). "Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents." PLoS One **8**(6): e66019.

Hooks, K. B., et al. (2019). "Microbiota-gut-brain research: a critical analysis." Behavioral and Brain Sciences **42**: e60.

Iliodromiti, Z., et al. (2023). "Gut microbiome and neurodevelopmental disorders: a link yet to be disclosed." Microorganisms **11**(2): 487.

Janeiro, M. H., et al. (2018). "Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target." Nutrients **10**(10): 1398.

Johnson, K. V.-A. (2020). "Gut microbiome composition and diversity are related to human personality traits." Human Microbiome Journal **15**: 100069.

Kadry, H., et al. (2020). "A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity." Fluids and Barriers of the CNS **17**(1): 1-24.

Kaur, H., et al. (2021). "Gut microbiome-mediated epigenetic regulation of brain disorder and application of machine learning for multi-omics data analysis." Genome **64**(4): 355-371.

Kieling, C., et al. (2008). "Neurobiology of attention deficit hyperactivity disorder." Child and adolescent psychiatric clinics of North America **17**(2): 285-307.

Kumar, K. S., et al. (2012). "Depression-symptoms, causes, medications and therapies." The Pharma Innovation **1**(3, Part A): 37.

Kuwahara, A., et al. (2020). "Microbiota-gut-brain axis: Enteroendocrine cells and the enteric nervous system form an interface between the microbiota and the central nervous system." Biomedical Research **41**(5): 199-216.

Leclercq, S., et al. (2020). "Gut microbiota-induced changes in β-hydroxybutyrate metabolism are linked to altered sociability and depression in alcohol use disorder." Cell Reports **33**(2).

Liu, F., et al. (2019). "Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer." International journal of biological sciences **15**(11): 2381.

Liu, T., et al. (2020). "Influence of gut microbiota on mental health via neurotransmitters: A review." Journal of Artificial Intelligence for Medical Sciences **1**(1-2): 1-14.

Man, W. H., et al. (2017). "The microbiota of the respiratory tract: gatekeeper to respiratory health." Nature Reviews Microbiology **15**(5): 259-270.

Marć, M. A., et al. (2022). "Does the gut microbial metabolome really matter? The connection between GUT metabolome and neurological disorders." Nutrients **14**(19): 3967.

Martins, B. P., et al. (2020). "The role of marine omega-3 in human neurodevelopment, including Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder–a review." Critical Reviews in Food Science and Nutrition **60**(9): 1431-1446.

Marwede, H., et al. (2022). Modulation of gut–brain axis through prebiotics and psychobiotics. Gut–Brain Connection, Myth or Reality? Role of the Microbiome in Health and Disease, World Scientific**:** 169-194.

Mathee, K., et al. (2020). "The gut microbiome and neuropsychiatric disorders: implications for attention deficit hyperactivity disorder (ADHD)." Journal of medical microbiology **69**(1): 14.

Mirzaei, M. K. and C. F. Maurice (2017). "Ménage à trois in the human gut: interactions between host, bacteria and phages." Nature Reviews Microbiology **15**(7): 397-408.

Munawar, N., et al. (2021). "Hidden role of gut microbiome dysbiosis in schizophrenia: Antipsychotics or psychobiotics as therapeutics?" International Journal of Molecular Sciences **22**(14): 7671.

Naganska, E. and E. Matyja (2011). "Amyotrophic lateral sclerosis–looking for pathogenesis and effective therapy." Folia Neuropathologica **49**(1): 1-13.

Nagel, M., et al. (2010). "Virus vasculopathy and stroke: an under-recognized cause and treatment target." Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders) **10**(2): 105-111.

Needham, B. D., et al. (2020). "Gut microbial molecules in behavioural and neurodegenerative conditions." Nature Reviews Neuroscience **21**(12): 717-731.

Okolie, C. L., et al. (2017). "Prospects of brown seaweed polysaccharides (BSP) as prebiotics and potential immunomodulators." Journal of Food Biochemistry **41**(5): e12392.

Oriach, C. S., et al. (2016). "Food for thought: The role of nutrition in the microbiota-gut–brain axis." Clinical Nutrition Experimental **6**: 25-38.

Paquet, J.-C., et al. (2021). "Entering first-in-human clinical study with a single-strain live biotherapeutic product: input and feedback gained from the EMA and the FDA." Frontiers in Medicine **8**: 716266.

Parker, A., et al. (2020). "Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health." Gut Microbes **11**(2): 135-157.

Patangia, D. V., et al. (2022). "Impact of antibiotics on the human microbiome and consequences for host health." MicrobiologyOpen **11**(1): e1260.

Patrono, E., et al. (2021). "Schizophrenia, the gut microbiota, and new opportunities from optogenetic manipulations of the gut-brain axis." Behavioral and Brain Functions **17**(1): 7.

Pelphrey, K. A., et al. (2011). "Research review: constraining heterogeneity: the social brain and its development in autism spectrum disorder." Journal of Child Psychology and Psychiatry **52**(6): 631-644.

Peng, M., et al. (2020). "Effectiveness of probiotics, prebiotics, and prebiotic-like components in common functional foods." Comprehensive Reviews in Food Science and Food Safety **19**(4): 1908-1933.

Pithadia, A., et al. (2009). "Pathogenesis and treatment of multiple sclerosis (MS)." Int J Neurol **10**(2): 1-20.

Rahman, M. M., et al. (2022). "Microbiome in cancer: Role in carcinogenesis and impact in therapeutic strategies." Biomedicine & Pharmacotherapy **149**: 112898.

Requena, T. and M. Velasco (2021). "The human microbiome in sickness and in health." Revista Clínica Española (English Edition) **221**(4): 233-240.

Rinninella, E., et al. (2019). "What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases." Microorganisms **7**(1): 14.

Rogers, G., et al. (2016). "From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways." Molecular psychiatry **21**(6): 738-748.

Rutsch, A., et al. (2020). "The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology." Frontiers in Immunology **11**: 604179.

Sanz, Y. and G. De Palma (2009). "Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function." International reviews of immunology **28**(6): 397-413.

Schepici, G., et al. (2019). "The gut microbiota in multiple sclerosis: an overview of clinical trials." Cell Transplantation **28**(12): 1507-1527.

Schneider, S., et al. (2019). "Unexpected roles for the second brain: enteric nervous system as master regulator of bowel function." Annual review of physiology **81**: 235-259.

Senghor, B., et al. (2018). "Gut microbiota diversity according to dietary habits and geographical provenance." Human Microbiome Journal **7**: 1-9.

Silva, Y. P., et al. (2020). "The role of short-chain fatty acids from gut microbiota in gut-brain communication." Frontiers in endocrinology **11**: 25.

Simon, D. W., et al. (2017). "The far-reaching scope of neuroinflammation after traumatic brain injury." Nature Reviews Neurology **13**(3): 171-191.

Singh, N., et al. (2022). "Deciphering the gut microbiome in neurodegenerative diseases and metagenomic approaches for characterization of gut microbes." Biomedicine & Pharmacotherapy **156**: 113958.

Sivamaruthi, B. S., et al. (2020). "The role of microbiome, dietary supplements, and probiotics in autism spectrum disorder." International journal of environmental research and public health **17**(8): 2647.

Socała, K., et al. (2021). "The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders." Pharmacological Research **172**: 105840.

Strandwitz, P. (2018). "Neurotransmitter modulation by the gut microbiota." Brain research **1693**: 128-133.

Suganya, K. and B.-S. Koo (2020). "Gut–brain axis: role of gut microbiota on neurological disorders and how probiotics/prebiotics beneficially modulate microbial and immune pathways to improve brain functions." International Journal of Molecular Sciences **21**(20): 7551.

Sun, L.-J., et al. (2020). "Gut hormones in microbiota-gut-brain cross-talk." Chinese medical journal **133**(07): 826-833.

Tan, A. H., et al. (2022). "The microbiome–gut–brain axis in Parkinson disease—from basic research to the clinic." Nature Reviews Neurology **18**(8): 476-495.

Tilg, H., et al. (2016). "Gut microbiome and liver diseases." Gut **65**(12): 2035-2044.

Tkach, S., et al. (2023). Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option. Microbiome in 3P Medicine Strategies: The First Exploitation Guide, Springer**:** 275-308.

Ullah, H., et al. (2023). "The gut microbiota–brain axis in neurological disorder." Frontiers in neuroscience **17**.

Van Karnebeek, C. D., et al. (2014). "The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource." Molecular genetics and metabolism **111**(4): 428-438.

VanPatten, S. and Y. Al-Abed (2017). "The challenges of modulating the 'rest and digest'system: acetylcholine receptors as drug targets." Drug discovery today **22**(1): 97-104.

Varesi, A., et al. (2023). "The Brain-Gut-Microbiota Interplay in Depression: a key to design innovative therapeutic approaches." Pharmacological Research: 106799.

Wall, R., et al. (2014). "Bacterial neuroactive compounds produced by psychobiotics." Microbial endocrinology: The microbiota-gut-brain axis in health and disease: 221-239.

Xiong, R.-G., et al. (2022). "Health benefits and side effects of short-chain fatty acids." Foods **11**(18): 2863.

Ye, X., et al. (2022). "Dual role of indoles derived from intestinal microbiota on human health." Frontiers in Immunology **13**: 903526.

Yoo, J. Y., et al. (2020). "Gut microbiota and immune system interactions." Microorganisms **8**(10): 1587.

Zhang, Y., et al. (2023). "Metabolite interactions between host and microbiota during health and disease: Which feeds the other?" Biomedicine & Pharmacotherapy **160**: 114295.

Zhao, J., et al. (2021). "The Impact of Gut Microbiota on Post-Stroke Management." Frontiers in cellular and infection microbiology **11**: 724376.

Zheng, D., et al. (2020). "Interaction between microbiota and immunity in health and disease." Cell research **30**(6): 492-506.

Zhu, B., et al. (2010). "Human gut microbiome: the second genome of human body." Protein & cell **1**(8): 718-725.

Zhu, F., et al. (2020). "Target dysbiosis of gut microbes as a future therapeutic manipulation in Alzheimer's disease." Frontiers in aging neuroscience: 302.

Zis, P. and A. Strydom (2018). "Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome." Free Radical Biology and Medicine **114**: 3-9.

Zubeldia-Varela, E., et al. (2020). "Sample pre-treatment procedures for the omics analysis of human gut microbiota: Turning points, tips and tricks for gene sequencing and metabolomics." Journal of Pharmaceutical and Biomedical Analysis **191**: 113592.